Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 May;65(5):2225-30.
doi: 10.1128/JVI.65.5.2225-2230.1991.

Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus

Affiliations

Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus

M Torten et al. J Virol. 1991 May.

Abstract

Within 6 months of infection with the Petaluma isolate of feline immunodeficiency virus, specific-pathogen-free domestic cats exhibited a decrease in the percentage and number of circulating CD4+ lymphocytes and in the CD4+/CD8+ T-cell ratio, along with a marginally significant depression of pokeweed mitogen-induced lymphocyte proliferation in vitro. There was no loss of responsiveness to concanavalin A during this stage, and the cats were capable of mounting a satisfactory antibody response to a T-dependent, synthetic polypeptide immunogen. The pokeweed mitogen response deficit became clearly demonstrable by 11 to 12 months postinfection. A decline in the lymphocyte proliferative response to concanavalin A and a diminished ability to mount an in vivo antibody response to the T-dependent immunogen evolved by 25 to 44 months postinfection. Virus infection did not affect the ability of cats to mount an antibody response to a T-independent synthetic polypeptide immunogen. These data indicate that feline immunodeficiency virus produces a slowly progressive deterioration of T-cell function but does not affect the ability of B cells to recognize and respond to a T-independent antigenic stimulus.

PubMed Disclaimer

References

    1. FASEB J. 1989 Dec;3(14):2593-606 - PubMed
    1. J Med Virol. 1989 Jun;28(2):96-100 - PubMed
    1. JAMA. 1987 May 15;257(19):2617-21 - PubMed
    1. Science. 1986 Sep 5;233(4768):1084-6 - PubMed
    1. J Clin Invest. 1988 Dec;82(6):1908-14 - PubMed

Publication types

MeSH terms